Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP
Professor of Pharmacy Practice, Clinical Pharmacist, Well Life
School
School of Pharmacy
Department
Pharmacy Practice
Office Location
White 347
Boston
Office Phone Office Phone: 617.732.2917
Website Website:
About
Dr. Goldman is a professor of pharmacy who teaches in the pharmacy and physician assistant programs. She is a clinical pharmacist/director of the Cardiometabolic Program at Well Life in Peabody, where she trains and precepts PharmD students, residents and fellows. Dr. Goldman has been practicing for over 30 years and completed her residency at the Boston VAMC. She is board certified in advanced diabetes management, is a Certified Diabetes Care and Education Specialist and a fellow of ACCP. She has presented at local, national and international pharmacy and medical conferences and has served on state and national public health and diabetes boards. Dr. Goldman has received multiple internal and external awards and has numerous publications in the areas of diabetes, cardiovascular disease and education.
Education
- Bachelor of Science in Pharmacy
- Doctor of Pharmacy
- Pharmacy Practice Residency, emphasis in ambulatory care, Boston VA Medical Center
- Certified Diabetes Care and Education Specialist (CDCES) Board Certified in Advanced Diabetes Management (BC-ADM)
- APhA Pharmacist and Patient Centered Care Diabetes Certificate Program, trainer
Research Interests
- diabetes
- cardiometabolic disease
- teaching
Featured Affiliations
American College of Clinical Pharmacy (ACCP)
WebsiteEndocrine and Metabolism PRN group of ACCP
WebsiteEducation
- Bachelor of Science in Pharmacy
- Doctor of Pharmacy
- Pharmacy Practice Residency, emphasis in ambulatory care, Boston VA Medical Center
- Certified Diabetes Care and Education Specialist (CDCES) Board Certified in Advanced Diabetes Management (BC-ADM)
- APhA Pharmacist and Patient Centered Care Diabetes Certificate Program, trainer
Research Interests
- diabetes
- cardiometabolic disease
- teaching
Publications
- Goldman JD, Busch R, Miller E. Best Practice Perspectives on Improving Early Detection and Management of Chronic Kidney Disease Associated With Type 2 Diabetes in Primary Care. Published ahead of print 01/12/24. Clin Diabetes. 2024. https://doi.org/10.2337/cd23-0074
- Zhang A, El Hachem R, Goldman J. Preventing and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 2 Diabetes: Promising Therapeutic Agents and Strategies. Published ahead of print 12/8/23. ADCES in Practice. 2023;0(0). https://doi.org/10.1177/2633559X231213071
- Ojashwi G, Goldman JD. Donislecel: First Cellular Therapy to Treat Patients With Brittle Type 1 Diabetes. Published ahead of print 11/28/23. Clinical Diabetes. 2023;cd230091. https://doi.org/10.2337/cd23-0091
- Pavlakis, G., Goldman JD. Diabesity treatments today and tomorrow. Published ahead of print 10/4/23. ADCES in Practice. 2023;11(6):26-32. https://doi.org/10.1177/2633559X231202497
- Goldman JD, Choi H. Teplizumab: The first treatment to delay the progression of type 1 diabetes. Published ahead of print 5/16/23. Clin Diabetes. 2023;41(3):474-476. https://doi.org/10.2337
- Goldman JD. Deniabetes. (Editorial) Clin Diabetes. Published ahead of print 05/04/23. https://doi.org/10.2337/cd23-0017
- Edelman S, Goldman JD, Malone D, Preblick R, Munaga K, Li X, Gill J, Gangi S. Real-World Persistence, Adherence, Healthcare Resource Utilization, and Hypoglycemia in People with Type 2 Diabetes Who Continued the Second-Generation Basal Insulin Analog Insulin Glargine 300 U/mL or Switched to a First-Generation Basal Insulin Analog (Insulin Glargine 100 U/mL or Detemir). Clin Diabetes 2023. Published ahead of print 03/23/2023. https://doi.org/10.2337/cd22-0096
- Goldman JD, Angueira-Serrano E, Gonzalez J, Pang C, Tait J, Edelman S. Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin. Clin Diabetes. 2022. Published ahead of print 12/06/2022. https://doi.org/10.2337/cd22-0062
- Goldman JD, Sangave N. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. Clin Diabetes. 2022. Published ahead of print 11/10/2022. https://doi.org/10.2337/cd22-0049
- Martinez A, Goldman JD. Efficacy and Durability of Combination Treatment With Glucagon- Like Peptide-1 Receptor Agonists and Basal Insulin. ADCES in Practice. 2022;0(0). Published online ahead of print 10/1/2022. doi:10.1177/2633559X221127992
- Prisco JL, Goldman JD, Eguale T, Carace N. Important Factors in Remote Experiential Education. Pharmacy. 2022; 10(5):122. https://doi.org/10.3390/pharmacy10050122
- Choi H, Goldman J. Effects of antidiabetic medications on the risk of bone fracture in patients with type 2 diabetes mellitus. ADCES in Practice. 2022;0(0). Published online ahead of print 9/24/2022. https://doi.org/10.1177/2633559X221122789
- Brunton S, Fishbane S, Goldman JD, Wright E. Anemia in CKD in Primary Care: Executive Summary. Clin Diabetes 2022;cd220054. https://doi.org/10.2337/cd22-0054. Published online ahead of print 9/9/2022.
- Goldman JD, Dvorkin Camiel L. A new medical probiotic formulation for the management of type 2 diabetes. Available ahead of print 8/2/22. Clin Diabetes 2022; cd220070. https://doi.org/10.2337/cd22-0070
- Dvorkin Camiel L, Taglieri C, Kostka-Rokosz M, Tataronis G, Goldman J. Relationship between pharmacy students’ resilience scores and their leadership, work experience and academic performance. Industry and Higher Education; 2022;0(0):1-8. https://doi.org/10.1177/09504222221113491
- Goldman JD. Continuous glucose monitoring metrics: Interpretation and integrations. Am J Manag Care. 2022;28(4):S69-S75.
- Nigro S, Goldman JD. Linagliptin-induced arthralgia. doi.org/10.2337/cd20-0110 Published
ahead of print. 2021 Jul. Clin Diabetes. 2022;40(1):109-112. - Goldman JD, Patel D, Shah V. Basal insulin therapy in type 2 diabetes management: What the pharmacist should know. Pharmacy Times, September 2021. Available online at: https://www.pharmacytimes.com/view/basal-insulin-therapy-in-type-2-diabetes-management- what-the-pharmacist-should-know.
- Khzouz A, Rickson M, Sieradzan R, Goldman JD. Injection force variability: An overlooked aspect of proper insulin injection technique. doi.org/10.1177/2633559X20972353. ADCES in Practice. 2021;9(2);42-47.
- Shealy KM, Phillips CM, Bzowyckyi AS, Gupta V, Guyton J, Westberg SM, Cai C, Trujillo J, Goldman JD. Endocrine pharmacotherapy education in United States colleges and schools of pharmacy. J Am Coll Clin Pharm. 2021:1-9. doi: 10.1002/jac5.1393 . Published ahead of print February 2021. J Am Coll Clin Pharm. 2021;4:481-489.
- Pass A, Bialonczyk D, Chiquette E, Goldman JD. Oral superabsorbent hydrogel (Plenity) for weight management. Ann Pharmacother. doi.org/10.1177/1060028020983046. Published ahead of print, December, 2020. Ann Pharmacother. 2021;55(9):1146-1152.
- Goldman JD. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. J Clin Pharm Ther. doi.org/10.1111/jcpt.13226. Published online ahead of print, September 2020. J Clin Pharm Ther. 2020;45(Suppl 1):61-72.
- Schumacher C, Van Dril E, Shealy K, Goldman JD. Optimizing management of type 2 diabetes and its complications in patients with heart failure. doi.org/10.2337/cd20-0008. Published online ahead of print, August 2020. Clinical Diabetes Jan 2021, 39 (1) 105-116.
- Goldman JD, Harte F. Transition of care to prevent recurrence after acute coronary syndrome; the critical role of the primary care provider and pharmacist. Postgraduate Medicine. doi.org/10.1080/00325481.2020.1740512. Published online ahead of print, March 2020. Postgrad Med. Jun 2020;132(5);426-432.
- Lu B, Goldman JD. Glucose variability and the use of continuous glucose monitors in people
with type 1 and type 2 diabetes. Published ahead of print, AADE in Practice. October 2018. doi.org/10.1177/2325160318798641. 2018;6(6):22-25. AADE in Practice. 2018;6(6):22-25. - Morse C, Sze D, Patel D, Goldman JD. Non-glycemic benefits of antidiabetic medications. Published ahead of print, Clinical Diabetes, October 2018. doi.org/10.2337/cd18-0015. Clinical Diabetes. 2018;37(2):131-141.
- Goldman JD, Gill J, Horn T, Reid T, Strong J, Polonsky W. Improved treatment engagement among patients treated with insulin glargine 300U/ml who received live support through the COACH support program. doi.org/10.1007/s13300-018-0501-6. Diabetes Ther. 2018;9(5):2143-2153.
- White J, Goldman JD. Biosimilar and follow-on insulin: The ins, outs and interchangeability. Published ahead of print, Journal of Pharmacy Technology, September 2018. doi.org/10.1177/8755122518802268. J Pharm Technol. 2019;35(1): 25–35.
- Goldman JD. Antihyperglycemic medications for cardiovascular disease risk reduction. Am J Manag Care. 2018;24-S273-S278.
- Sze D, Goldman JD. Human regular 500 units/ml insulin therapy. A review of clinical evidence and new delivery options. Clinical Diabetes, published ahead of print August doi.org/10.2337/cd18-0004. Clinical Diabetes 2018:36(4):319-324.
- Goldman JD. Combination of empagliflozin and metformin therapy: A consideration place in type 2 diabetes therapy. Clinical Medicine Insights: Diabetes and Endocrinology 2018. Published online ahead of print July 2018. doi.org/10.1177/1179551418786258. Clinical Medicine Insights: Diabetes and Endocrinology 2018;11:1-11.
- Kerliu L, Goldman JD. Capecitabine and warfarin interaction: A review of literature and recommendations. Pharmacy Times 2018;7(3):10.
- Lu B, Goldman JD. Counseling patients with type 1 diabetes. Pharmacy Times
2018;84(2):37-38. - Lu B, Goldman JD. Pharmacists and Annual Wellness Visits. Pharmacy Times 2018;84(3):46-47.
- Patel D, Goldman JD, Fixed-ratio combination of basal insulin and GLP-1 receptor agonist. Pharmacy Times. 2017; 6(5)12-14.
- Valentine V, Goldman JD, Shubrook J. Rationale for initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Published online ahead of print July 2017 doi.org/10.1007/s13300-017- 0287-y, Diabetes Ther. 2017: 8(4)739-752.
- Goldman JD, Trujillo J. iGlarLixi: a fixed-ratio combination of insulin glargine 100U/ml and lixisenatide for the treatment of type 2 diabetes. Published online ahead of print June 2017, Ann Pharmacother. 2017;51(11):990-999. doi.org/10.1177/1060028017717281.
- Patel D, Goldman JD. Managing diabetes with insulin/glucagon-like peptide-1 receptor agonist combinations: the role of the pharmacist. Pharmacy Times. 2017; June (74-86). Pharmacy Times CE, 2-hours, June 2017. Available at https://pharmacytimes.org/landing/974
- Goldman JD, Kapitza C, Pettus J, Heise T. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. doi:10.1080/03007995.2017.1335192, Curr Med Res Opin. 2017;33(10):1821-1831.
- Trujillo J, Goldman JD. Lixisenatide, a once daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes. doi.org/10.1002/phar.1962. Pharmacotherapy. 2017;37(8):927-943.
- Dvorkin Camiel L, Kostka-Rokosz M, Tataronis G, Goldman JD. Performance and perceptions of student teams created and stratified based on academic abilities. AJPE, 2017;81(3):1-7. Article 47. doi:10.5688/ajpe81347
- Taglieri C, Schnee D, Dvorkin Camiel L, Zaiken K, Mistry A, Nigro S, Tataronis G, Patel D, Jacobson S, Goldman JD. Comparison of long-term knowledge retention in lecture-based versus flipped team-based learning course delivery. Currents in Pharmacy Teaching & Learning, 2017;9(3):391-397. doi.org/10.1016/j.cptl.2017.01.007
- Goldman JD, White J. Advances in basal insulin therapy. Journal of Pharmacy Technology, 2016;32(6):260-268. doi.org/10.1177/8755122516667128
- Oleck J, Kassam S, Goldman JD. Commentary: Why was inhaled insulin a failure in the
market? Diabetes Spectrum, 2016;Aug;29(3):180-184. doi.org/10.2337/diaspect.29.3.180 - Natali K, Goldman JD. Insulin allergy: A case report and review of the literature. Journal of Pharmacy Technology 2016:32(5):210-215. doi.org/10.1177/8755122516655544
- Bialonczyk D, Ourfalian K, Goldman JD. The artificial pancreas- current projects, challenges, and practical considerations. AADE in Practice, 2016; July; Vol 4 (4):50-54. doi.org/10.1177/2325160316650280
- Dvorkin Camiel L, Mistry A, Schnee D, Tataronis G, Taglieri C, Zaiken K, Patel D, Nigro S, Jacobson S, Goldman JD. Students’ attitudes, academic performance and preferences for content delivery in a very large self-care course redesign. AJPE 2016;80(4):1-8, Article 67. doi.org/ 10.5688/ajpe80467
- Patel D, Charkoudian M, Goldman JD, Couris R. Focus on hypoglycemia: Patient ed disease management and prevention. Nutr Today. 2015;50(6):277-281. doi.org/10.1097/NT.0000000000000132
- Goldman JD, White J. New insulin glargine 300 U/ml for the treatment of type 1 and type 2 diabetes mellitus. Doi.org/10.1177/1060028015597915. Ann Pharmacother. 2015;49(10):1153-1161.
- Shaikh N, Goldman JD. Current therapy in diabetes. On the Cutting Edge (OTCE) Diabetes Care and Education- Academy of Nutrition and Dietetics; 2015;36(2):4-7.
- Goldman JD, Horn D. Overcoming challenges and barriers to insulin therapy in type 2
diabetes. Pharmacy Times; 2015; 81(5):89-100. - Goldman-Levine JD. Combination therapy when metformin is not an option for type 2 diabetes. Ann Pharmacother; 2015; May; Vol. 49(6); 688-699. doi.org/10.1177/1060028015572653
- Dinsmore S, Grams K, Goldman-Levine JD, Couris RR. An overview of glycemic goals and medications used to manage type 2 diabetes. Nutrition Today; 2015; Jan/Feb;Vol 50(1):40-48. doi.org/10.1097/NT.0000000000000074
- Sparkes S, Goldman-Levine JD. Breaking down barriers: A second attempt at inhaled insulin. AADE in Practice, 2015; Jan; Vol 3 (1):44-47. doi.org/10.1177/2325160314558583
- Shaikh N, Goldman-Levine JD. Ready, aim, inject! All about needles and syringes. Diabetes
Self-Management 2014; Dec; 16-23. - Saunders T, Czarnowski J, Gold K, Hill JV, Jenkins C, Rhinehart AS, Goldman-Levine JD. AADE Recommendations for community-based screening for prediabetes and diabetes. AADE White Paper, issued December 1, 2014. Available at https://www.diabeteseducator.org/practice/practice-documents/practice-papers
- Goldman-Levine JD, Insulin Pen Problem. Expert Questions and Answers. Diabetes Self- Management: 2014; Oct: 75.
- Shaikh N, Goldman-Levine JD. Metformin-induced vitamin B12 deficiency. AADE in practice: 2014; Sept: Vol 2 (5); 38-41. doi.org/10.1177/2325160314545533
- Shaikh N, Goldman-Levine JD. Insulin injection technique for adults and children with diabetes. Practical Diabetology. 2014; (Sept/Oct) Vol 33(3):19-21.
- Sparkes S, Patel D, Goldman-Levine JD. Past, present and future research avenues for metformin: A literature review. Journal of Pharmacy Technology: 2014; Dec; 30;227-234. doi.org/10.1177/8755122514544527
- Dvorkin Camiel L, Goldman-Levine JD, Kostka-Rokosz M, McCloskey W, Tataronis G. Use of Twitter to Create a Personal Learning Network in a Required Pharmacy Course. Currents in Pharmacy Teaching and Learning. 2014; (July/August) 6 (4); 463-470. doi.org/10.1016/j.cptl.2014.04.008
- Dvorkin Camiel L, Goldman-Levine JD, Kostka-Rokosz M, McCloskey W. Twitter as an In- class Backchannel Tool in a Large Required Pharmacy Course. Amer J of Pharm Educ. 2014; 78(3) Article 67. doi.org/10.5688/ajpe78367
- Goldman-Levine JD. Insulin patch pumps: A new tool for type 2. Diabetes Self- Management. 2014; (March/April):10-14. Available at: http://www.diabetesselfmanagement.com/diabetes-resources/tools-tech/insulin-patch- pumps/
- Sparkes S, Lyden-Fortier S, Goldman-Levine JD. When diet and exercise are just not enough: New medications for weight loss. AADE in practice. 2013:42-45. doi.org/10.1177/2325160313506000
- Goldman-Levine JD. Introduction. In Individualizing therapy for the patient with type 2 diabetes: Focus on insulin, emerging therapies, and patient management. US Pharmacist. 2013;(suppl):4-6.
- Goldman-Levine JD. Basal insulin: Historic use and emerging therapies. In Individu therapy for the patient with type 2 diabetes: Focus on insulin, emerging therapies, and management. US Pharmacist. 2013;(suppl): 7-14.
- Riche D, Goldman-Levine JD. Uncovering and Managing Hypoglycemia: The Pharmacists Role. In Individualizing therapy for the patient with type 2 diabetes: Focus on insulin, emerging therapies, and patient management. US Pharmacist. 2013;(suppl): 21-29.
- Goldman-Levine JD. Canagliflozin: A new drug for type 2 diabetes. Diabetes Self- Management. 2013; July/Aug:30-32.
- Dvorkin Camiel L, Goldman-Levine JD. Herbal products for the treatment of type 2 diabetes.
Practical Diabetology. 2013;32(2):25-30. - Goldman-Levine JD. Patel D, Schnee D. Insulin degludec: A novel insulin analogue. Ann Pharmacother. 2013;47(2):269-277. doi.org/10.1345/aph.1R351
- Patel D, Goldman-Levine JD. Fidaxomicin (Dificid) for clostridium difficile. Am Fam Physician. 2013;87(3):211-212.
- Goldman-Levine JD, Dvorkin Camiel L. Patented medicine (complementary and alternative medicine for the treatment of type 2 diabetes). Diabetes Self-Management. 2012;Sept/Oct:42-43. Republished in Practical Diabetology. 2013;Mar/Apr: 25.
- Obua U, Sabackic M, Goldman-Levine JD. Integrated learning modules to increase involvement in ASHP student society. AJHP. 2012;69:277. doi.org/10.2146/ajhp110534
- Goldman-Levine JD. Beyond metformin; initiating combination therapy in patients with type 2 diabetes. Pharmacotherapy. 2011;31:44S-53S. doi.org/10.1592/phco.31.12.44S
- Saliu D, Goldman-Levine JD. Viewpoint: It’s now or never. Drug Topics 2011; 155(7):60.
- Diabetes Guidelines Work-Group, Diabetes Prevention and Control Program: Massachusetts Guidelines for Adult Diabetes Care 2011; Executive Summary of Revisions and Recommendations. Produced by the Health Promotion Clearinghouse. The Medical Foundation. Available at: http://www.maclearinghouse.com/PDFs/Diabetes/2011_Executive_Summary.pdf.
- Patel D, Goldman-Levine JD. Doxepin (silenor) for insomnia. Am Fam Physician.
2011;84(4):453-4. - Goldman-Levine JD. Overmedicated (multidrug therapy). Expert Questions and Answers. Diabetes Self-Management: 2010:Nov/Dec:62-63.
- Edwards KL, Riche DM, Stroup JS, Goldman-Levine JD, Padiyara RS, Cross LB, Kane MP. Insulin glargine and cancer risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy: 2010;30(9):955-965.
- Diabetes Guidelines Work-Group, Diabetes Prevention and Control Program: Massachusetts Guidelines for Adult Diabetes Care 2009. Produced by the Health Promotion Clearinghouse. The Medical Foundation. Available at: http://www.maclearinghouse.com/PDFs/Diabetes/June2009%20ADULT%20GL.pdf.
- Goldman-Levine JD. Insulin Pen Doses. Expert Questions and Answers. Diabetes Self- Management: 2009:Sept/Oct:55-56.
- Cheng J, Bhatt S, Goldman-Levine JD, The benefit and risk of antidiabetic agents used in
patients with heart disease. Journal of Pharmacy Practice. 2009:22;(2):179-193. - Goldman-Levine JD. Zoledronic acid for osteoporosis. American Family Physician: 2008:78(4):508-509.
- Pareira CE, Goldman-Levine JD. Case Report, letter: Venlafaxine extended release induced alopecia. Annals of Pharmacotherapy:2007;41:1084.
- Diabetes Guidelines Work-Group, Diabetes Prevention and Control Program: Massachusetts Guidelines for Adult Diabetes Care 2007. Produced by the Health Promotion Clearinghouse. The Medical Foundation. Available at: http://www.maclearinghouse.com/PDFs/Diabetes/GuidelinesFY07/DB723_2007.pdf.
- Goldman-Levine JD. Insulin detemir for diabetes mellitus. American Family Physici 2006;74(2):323-324.
- Goldman-Levine JD, Bohlman LG. Ezetimibe/Simvastatin for cholesterol. American Family Physician: 2005;72(10):2081-2082.
- Goldman-Levine JD, Lee KW. Insulin Detemir—A New Basal Insulin Analog. Ann Pharmacother: 2005;39(3):502-7.
- Lemieux A, Goldman-Levine JD, Gorren J. Aripiprizole: An antipsychotic with a novel mechanism of action. J Pharm Technol 2003;19:365-72.
- Bechara C, Goldman-Levine JD. Case Report: Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Pharmacotherapy 2001;21(11):1444-1447.
Awards and Honors
- MCPHS Faculty Award for Scholarship of Application. Discovering ways that new knowledge can be used to solve real world problems. For the research “Improved treatment engagement among patients receiving insulin glargine 300 units/ml who enrolled and received live support through the coach patient support program”, 5/18
- MCPHS Faculty Award for Scholarship of Integration/Engagement. Interpreting the use of knowledge across disciplines and preparing a comprehensive literature review. For paper “Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice”, 5/18
- Faculty Preceptor of the Year Award, MCPHS Biopharmaceutical Industry Fellowship Program,
June 16, 2016, In appreciation of your outstanding leadership and mentorship to the MCPHS Fellows at BD, 2016-2017 - MCPHS Faculty Award for Scholarship of Integration, MCPHS. Interpreting the use of knowledge across disciplines and preparing a comprehensive literature review. For paper “New insulin glargine 300 U/ml for the treatment of type 1 and type 2 diabetes”, 5/16
- FCCP, Fellow of the American College of Clinical Pharmacy. Inducted October 17, 2010, at the ACCP Annual Meeting, Austin, TX. Fellowship in the College recognizes and rewards the highest levels of excellence in the practice and science of Clinical Pharmacy. The awarding of Fellow status is the highest honor the College can bestow on its members.
- Pharmacy Practice Teacher of the Year Award, MCPHS, 5/09
- Long-Term Faculty Service Award, MCPHS, Given in recognition of long-standing, exceptional, dedicated and substantial service to the College, 5/08
- Recognition of Teaching in Family Medicine, AAFP, American Academy of Family Physicians, 6/05,
6/06, 6/07, 6/08, 6/09, 6/10, 6/11 - Recognition of Nomination for the U.S. Professors of the Year Award, U.S. Professors of the Year Awards Program celebrates extraordinary dedication to undergraduate teaching at higher education institutions in the United States. For years of excellent teaching, and demonstration of a passion for educating, a commitment to students, and innovative instructional methods that have inspired and motivated others, 2006
- Trustees Award for Teaching Excellence, MCPHS, Given in recognition of excellence in teaching effectiveness, course design and development, curriculum design, mentoring in teaching, and scholarly work in teaching, 5/05
- Phi Lambda Sigma Leadership Fraternity, MCPHS, 4/05
- Preceptor of the Year, MCPHS, Given in recognition of outstanding contributions to the educational development of future pharmacists by demonstrating high standards of professionalism, ethics and clinical practice by the MCPHS Class of 2002, 3/02
- RHO CHI Pharmacy Honor Society, PSI Chapter, MCPHS, induction 4/96
More Affiliations
- Ambulatory Care PRN group of ACCP
- American Diabetes Association (ADA)
- Association of Diabetes Care and Education Specialists (ACDES)
- New England Institute for Ambulatory Care Pharmacists (NEIAP)